Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7J6OR)

• Drug Name: Tocilizumab Drug Info
• Synonyms: Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody

Indication

Disease Entry	ICD 11	Status	REF
Giant cell arteritis	4A44.2	Approved	[1]
Rheumatoid arthritis	FA20	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
Juvenile idiopathic arthritis	FA24	Phase 3	[2]
Castleman's disease	4B2Y	Investigative	[4]

• Cross-matching ID: TTD Drug ID: DM7J6OR

Molecule-Related Drug Atlas

Drug(s) Targeting HUMAN interleukin-6 receptor (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[7]

Drug(s) Targeting Interleukin 6 receptor (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[8]
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[9]
SAR153191	DMXAO4J	Ankylosing spondylitis	FA92.0	Phase 3	[10]
SA-237	DM7F2VG	Encephalopathy	8E47	Phase 3	[11]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[12]
ALX-0061	DMO1VHC	Autoimmune diabetes	5A10	Phase 2	[13]
SBP-002	DM9F7R0	Melanoma	2C30	Terminated	[8]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[14]
FM-101	DMXK6EI	Multiple myeloma	2A83	Investigative	[9]
Sant7	DM9CV4P	Multiple myeloma	2A83	Investigative	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 6 receptor (IL6R)	TT0E5SK	IL6RA_HUMAN; IL6RB_HUMAN	Modulator	[5]
HUMAN interleukin-6 receptor (IL6R)	TTDVAKP	IL6RA_HUMAN; IL6RB_HUMAN	Inhibitor	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881).
• [3] ClinicalTrials.gov (NCT04320615) A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
• [4] Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020;98(3):131-137.
• [5] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [6] Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0.
• [7] IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
• [10] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [11] IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
• [12] Clinical pipeline report, company report or official report of Ablynx.
• [13] The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
• [14] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [15] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.